# PARTNER 3 trial

Study · id `cardio:partner-3` · Cardiovascular Atlas · release `f6f6f1b6f50379ed` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: PARTNER 3; P3; PARTNER 3 Trial: Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial that compared TAVR (with the SAPIEN 3 valve) against open-heart surgery in 1000 people with severe aortic stenosis who were at low risk from surgery. After one year, fewer people in the TAVR group had died, had a stroke or had gone back to hospital. It was paid for by Edwards Lifesciences, the applicant for the valve's US approval, and the registry lists no masking.

## Technical summary

Registry NCT02675114 (Edwards Lifesciences lead sponsor, class industry, status active but not recruiting, estimated completion 2029-12). Randomized, parallel, no masking, treatment. Abstract: noninferiority margin 6 percentage points, as-treated analysis; primary composite at 1 year 8.5% versus 15.1% (hazard ratio 0.54). Findings are not tabulated because the primary composite has no outcome record in this atlas.

## Key facts

- Design: Randomized, parallel-group, open-label trial of TAVR with a balloon-expandable valve versus surgical aortic valve replacement. The registry records allocation as randomized, intervention model as parallel and masking as none.
- Phase: Not applicable
- Enrolled: 1000 participants (enrolled count; PARTNER 3 Trial: Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis, snapshot `cardio:ctgov-nct02675114-2026-10-14`, retrieved 2026-10-14); 1000 patients (randomized count; Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients, snapshot `cardio:pubmed-30883058-2026-10-14`, retrieved 2026-10-14)
- Started: 2016-03 (actual) (PARTNER 3 Trial: Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis, snapshot `cardio:ctgov-nct02675114-2026-10-14`, retrieved 2026-10-14)
- Primary completion: 2020-11-16 (actual) (PARTNER 3 Trial: Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis, snapshot `cardio:ctgov-nct02675114-2026-10-14`, retrieved 2026-10-14)
- Completion: 2029-12 (anticipated) (PARTNER 3 Trial: Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis, snapshot `cardio:ctgov-nct02675114-2026-10-14`, retrieved 2026-10-14)
- Results first posted: 2021-12-02 (actual) (PARTNER 3 Trial: Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis, snapshot `cardio:ctgov-nct02675114-2026-10-14`, retrieved 2026-10-14)
- Countries: United States; Australia; Canada; Japan; New Zealand (PARTNER 3 Trial: Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis, snapshot `cardio:ctgov-nct02675114-2026-10-14`, retrieved 2026-10-14)
- Care setting: 71 centers (abstract); the registry lists sites in five countries. (Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients, snapshot `cardio:pubmed-30883058-2026-10-14`, retrieved 2026-10-14)
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), snapshot `cardio:ctgov-nct02675114-2026-10-14`, retrieved 2026-10-14)

## Connected pages

- Registry intervention: SAPIEN 3 THV: SAPIEN 3 transcatheter heart valve (`cardio:sapien-3`)
- Registry comparison: SAVR: Surgical aortic valve replacement (`cardio:surgical-aortic-valve-replacement`)
- Registry condition: aortic stenosis: Aortic stenosis (`cardio:aortic-stenosis`)
- Part of the primary outcome measure: Death from any cause (`core:outcome-death-any-cause`)
- Part of the primary outcome measure: Stroke as an outcome (`core:outcome-stroke`)
- Lead sponsor on the registry record: Edwards Lifesciences (`cardio:edwards-lifesciences`)
- Funder named in the abstract: Edwards Lifesciences (`cardio:edwards-lifesciences`)

## Provenance

Content hash: f6fc0de03113228fef457adea274334b5a882f5009950df33e2be0182e404267
Last substantive edit: 2026-10-15
Evidence last checked: 2026-10-14